Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vistagen Therapeutics (VTGN) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $19.8 million.

  • Vistagen Therapeutics' Operating Expenses rose 2927.58% to $19.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $70.7 million, marking a year-over-year increase of 3204.07%. This contributed to the annual value of $56.5 million for FY2025, which is 6564.18% up from last year.
  • Vistagen Therapeutics' Operating Expenses amounted to $19.8 million in Q4 2025, which was up 2927.58% from $20.3 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Operating Expenses peaked at $20.3 million during Q3 2025, and registered a low of $6.7 million during Q1 2021.
  • Over the past 5 years, Vistagen Therapeutics' median Operating Expenses value was $12.8 million (recorded in 2021), while the average stood at $13.1 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Operating Expenses soared by 26270.92% in 2021, and later plummeted by 6427.36% in 2023.
  • Quarter analysis of 5 years shows Vistagen Therapeutics' Operating Expenses stood at $10.9 million in 2021, then fell by 8.73% to $9.9 million in 2022, then decreased by 16.6% to $8.3 million in 2023, then soared by 85.1% to $15.4 million in 2024, then increased by 29.28% to $19.8 million in 2025.
  • Its Operating Expenses was $19.8 million in Q4 2025, compared to $20.3 million in Q3 2025 and $16.0 million in Q2 2025.